Comparison of pharmacological inhibitors of lysine-specific demethylase 1 in glioblastoma stem cells reveals inhibitor-specific efficacy profiles

IntroductionImproved therapies for glioblastoma (GBM) are desperately needed and require preclinical evaluation in models that capture tumor heterogeneity and intrinsic resistance seen in patients. Epigenetic alterations have been well documented in GBM and lysine-specific demethylase 1 (LSD1/KDM1A)...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Lea M. Stitzlein, Achintyan Gangadharan, Leslie M. Walsh, Deokhwa Nam, Alexsandra B. Espejo, Melissa M. Singh, Kareena H. Patel, Yue Lu, Xiaoping Su, Ravesanker Ezhilarasan, Joy Gumin, Sanjay Singh, Erik Sulman, Frederick F. Lang, Joya Chandra
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2023-04-01
coleção:	Frontiers in Neurology
Assuntos:	histone demethylase inhibitors epigenetics lysine specific demethylase (KDM) glioblastoma drug resistance
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fneur.2023.1112207/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!